{"id":"NCT04338269","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment","officialTitle":"A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-07-28","primaryCompletion":"2023-01-03","completion":"2025-03-24","firstPosted":"2020-04-08","resultsPosted":"2024-02-28","lastUpdate":"2025-04-04"},"enrollment":522,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Renal Cell"],"interventions":[{"type":"DRUG","name":"Atezolizumab","otherNames":["Tecentriq"]},{"type":"DRUG","name":"Cabozantinib","otherNames":["Cabometyx"]}],"arms":[{"label":"Atezo+Cabo","type":"EXPERIMENTAL"},{"label":"Cabozantinib","type":"ACTIVE_COMPARATOR"}],"summary":"This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of atezolizumab given in combination with cabozantinib versus cabozantinib alone in participants with inoperable, locally advanced, or metastatic renal cell carcinoma (RCC) who experienced radiographic tumor progression during or after Immune Checkpoint Inhibitor (ICI) treatment in the metastatic setting.","primaryOutcome":{"measure":"Progression Free Survival (PFS) as Assessed by an Independent Review Facility (IRF) (IRF-PFS) According to RECIST v1.1","timeFrame":"From randomization to the first occurrence of disease progression according to RECIST v1.1 (up to 2 years 5 months).","effectByArm":[{"arm":"Cabozantinib (Control)","deltaMin":10.81,"sd":null},{"arm":"Atezolizumab + Cabozantinib","deltaMin":10.55,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.7844"},{"comp":"OG000 vs OG001","p":"0.7195"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":13,"exclusionCount":22},"locations":{"siteCount":125,"countries":["United States","Argentina","Australia","Canada","Denmark","France","Germany","Greece","Italy","Japan","Poland","Russia","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["37290461","35304832"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":84,"n":256},"commonTop":["Diarrhoea","Palmar-plantar erythrodysaesthesia syndrome","Decreased appetite","Hypothyroidism","Nausea"]}}